Advanced AAV Processing and Potency through Characterisation of Capsid and Payload Heterogeneity
Enhancing adeno-associated virus (AAV) viral vector quality can significantly impact product efficacy and is essential to ensure patient safety. We invite you to join our team of experts for a deep dive into our AAV viral vector development expertise and showcase our recent breakthroughs.In this webinar, our speakers will delve into how the characterisation of the contents and surface of AAV capsids has helped identify factors influencing charge heterogeneity, and, consequently, the potency of AAV products:We will first present how VP1 deamidation, which has been associated with a decrease in potency, is also connected to hydrophobicityWe will investigate how production time within the bioreactor and AAV location inside or outside the cell affects capsid post-translational modifications and surface chargeWe will finally demonstrate the importance of reducing and controlling the level of intermediate (partially full) and empty capsids, which can impact product efficacy and have potential implications for patient safetyAfter the webinar, we will host a live Q&A session, providing attendees with the opportunity to ask questions directly to the presenters. We look forward to your participation.Who Should Attend?This webinar will appeal to professionals in the following fields or those having the following job titles:Biotechnology and pharmaceutical professionalsProject Managers/Technical ExpertsResearch & DevelopmentCell and Gene Therapy Program LeadersBusiness DevelopmentAcademicsWhat You Will LearnAttendees will learn about:Negative charge due to deamidation and hydrophobicity are related and impact capsids separationProduction duration and location of capsids at harvest affect AAV charge and potencyHow although intermediate capsids contribute to overall titer and are infectious, their payloads are not efficacious and thus considered a process-related impuritySpeakers: Sarah Laughlin-Toth - Senior Scientist II Analytical Development, Oxford Biomedica; Thomas Thiers - Scientist II Purification Sciences, Oxford Biomedica; Alex Meola - Associate Director, AAV Downstream Process Development, Oxford Biomedica.
